Table 3.
Selected candidate markers to create the proposed multivariate model.
| ESImode | m/z | RT (min) | p(FDR) | PDAC/HC | AUC | Tentativeidentification |
|---|---|---|---|---|---|---|
| + | 646.4145 | 7.65 | 1.65 × 10−15 | ↑ | 0.959 | PS(12:0/15:1) |
| - | 446.3760 | 9.44 | 3.75 × 10−14 | ↓ | 0.902 | TG(22:2/15:0/18:3) |
| - | 627.3741 | 3.53 | 7.46 × 10−15 | ↑ | 0.900 | 4-oxo-Retinoic acid |
| - | 369.1747 | 3.29 | 2.71 × 10−13 | ↓ | 0.878 | Androsterone sulfate |
| - | 476.2792 | 5.08 | 4.65 × 10−12 | ↓ | 0.859 | LysoPE(18:2) |
| - | 311.1396 | 2.62 | 6.27 × 10−17 | ↓ | 0.858 | Phenylalanylphenylalanine |
| + | 430.2939 | 7.58 | 7.08 × 10−10 | ↑ | 0.850 | all-trans-Decaprenyldiphosphate |
| + | 1039.6721 | 10.79 | 1.73 × 10−9 | ↓ | 0.848 | LysoPC(18:2) |
| - | 367.1583 | 3.14 | 1.79 × 10−9 | ↓ | 0.847 | Dehydroepiandrosterone sulfate |
ESI: electrospray ionization; RT: retention time; FDR: false discovery rate; PDAC: pancreatic ductal adenocarcinoma patients; HC: healthy controls; AUC: area under the curve; PS: phosphatidylserine; TG: triglyceride; LysoPE: lysophosphatidylethanolamine; LysoPC: lysophosphatidylcholine. PDAC/HC ratio shows increased (↑) or decreased (↓) levels of each marker in PDAC group compared to HC and based in fold change ratio.